作者
Jhanelle E Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B Haura, Ben Creelan, Scott J Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J Saller, Zhihua Chen, Nishan Tchekmedyian, Kristen Goas, Ram Thapa, Theresa A Boyle, Dung-Tsa Chen, Amer A Beg
发表日期
2019/11/15
期刊
Clinical Cancer Research
卷号
25
期号
22
页码范围
6623-6632
出版商
American Association for Cancer Research
简介
Purpose
Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs). In a phase I/Ib trial, we tested the oral HDACi vorinostat combined with the programmed cell death protein 1 inhibitor pembrolizumab in advanced/metastatic non–small cell lung cancer.
Patients and Methods
Patients received intravenous pembrolizumab (200 mg every 3 weeks) plus oral vorinostat (200 or 400 mg/day). Primary endpoint was safety/tolerability. Secondary endpoints included response rate, progression-free survival, disease control rate (DCR), and overall survival. Tumor gene expression changes, T-cell density, and myeloid cell levels were studied in serial tissue specimens.
Results
Thirty-three patients were treated (13 in phase I, 20 in phase Ib). In phase I, both ICI …
学术搜索中的文章
JE Gray, A Saltos, T Tanvetyanon, EB Haura… - Clinical Cancer Research, 2019